JPMorgan analyst Priyanka Grover initiates coverage on Relay Therapeutics (NASDAQ: RLAY) with a Overweight rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage